Chevy Chase Trust Holdings LLC Sells 106,786 Shares of Pfizer Inc. $PFE

Chevy Chase Trust Holdings LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 3.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,941,543 shares of the biopharmaceutical company’s stock after selling 106,786 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in Pfizer were worth $74,951,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of PFE. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer during the 3rd quarter valued at approximately $29,000. Howard Hughes Medical Institute bought a new position in shares of Pfizer in the 2nd quarter worth approximately $30,000. Darwin Wealth Management LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $32,000. Evelyn Partners Asset Management Ltd purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $33,000. Finally, True Wealth Design LLC boosted its position in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.0%

Pfizer stock opened at $26.60 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company has a market capitalization of $151.23 billion, a price-to-earnings ratio of 19.56 and a beta of 0.47. The business’s fifty day simple moving average is $26.50 and its two-hundred day simple moving average is $25.52. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s revenue was down 1.2% on a year-over-year basis. During the same period last year, the company earned $0.63 earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on PFE shares. Morgan Stanley decreased their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a report on Monday, March 2nd. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Finally, TD Cowen reissued a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.05.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.